Tag:

Aratana Therapeutics

Latest Headlines

Latest Headlines

Fast-growing Aratana beefs up pet drug pipeline with a $44M buyout

An acquisitive Aratana Therapeutics is buying up another biotech, beefing up its pipeline of experimental therapies for pets.

The top 10 biotech IPOs of 2013

Last year when we did the list of the top 10 biotech IPOs of 2012, we were lucky to have 10. Actually, there were 11, and that looked pretty good compared to the lean and hungry years of 2008 to...

UPDATED: Fresh burst of biotech IPO pitches launches a busy Q4 season

After a slight lull in the biotech IPO arena, new offerings came barreling back this week with some fresh breakouts. In particular Foundation Medicine priced over the range and immediately soared more than 80%. And Ophthotech also crested its range, erasing any lingering doubts about the short-term sustainability of the biotech IPO frenzy. Together they raised $273 million in a 24-hour pop. Read the report >>

Aratana adds pet therapies in $38M deal to acquire Vet

Aratana Therapeutics has struck a deal to buy San Diego-based Vet Therapeutics, adding new pet therapies to its pipeline for $30 million in cash, a chunk of stock, a promissory note for $3 million and up to $5 million in milestone payments.

The biotech IPO scene turns red hot

During all of last year there were only 11 biotech IPOs. But even that weak number looked pretty good compared to the barren years leading away from the 2008 financial crisis. In the last 6 months, though, the industry has seen a tremendous rebound, with almost twice that number of IPOs in half the time. And there's no sign that the great leap into the public market is waning, with 10 more IPOs in the queue. Read the full report >>

Aratana joins biotech IPO queue while Tetraphase takes a haircut

Aratana Therapeutics, which is developing six new treatments for cats and dogs, joined the biotech queue on Wall Street, filing an S-1 indicating a desire to raise $57.5 million in an IPO.

Aratana adds $15M in VC cash for new pet drug deals with biopharmas

A biotech upstart in Kansas City, KS has garnered $15 million in venture cash to fund deals that will take some of the therapies in development for humans and adapt them to the booming market for